EMICIZUMAB DATA
Additional Topics
Select publications and scientific data presentations with the strongest and most relevant data are provided below.
Hemophilia A With Other Coexisting Health Conditions
Emicizumab Is Efficacious in People With Hemophilia A With Comorbidities Aged ≥50 Years: Analysis of 4 Phase III Trials
Jiménez-Yuste V, Oldenburg J, Tzeng E, et al. Res Pract Thromb Haemost. 2024;8(3):102405.
Emicizumab in People With Moderate or Mild Haemophilia Aged ≥40 Years, With and Without Comorbidities
Jiménez-Yuste V, Tzeng E, Lim E, et al. Presented at EAHAD; February 6-9, 2024.
Bone Health and Physical Activity
TSUBASA Study: A Prospective Study Evaluating the Association Between Physical Activity and Bleeding Events, Quality of Daily Life, and Safety in People With Hemophilia A Without FVIII Inhibitors
Nogami K, Fujii T, Sawada A, et al. Presented at ASH; December 7-10, 2024.
Association of Physical Activity With Bleeding Events and Safety in Patients With Haemophilia A Starting Emicizumab Prophylaxis: An Interim Analysis of the TSUBASA Study
Nogami K, Fujii T, Sawada A, et al. Int J Hematol. 2024;119:14–23.
Effect of Emicizumab Prophylaxis on Bone and Joint Health Markers in People With Haemophilia A Without Factor VIII Inhibitors in the HAVEN 3 Study
Kiialainen A, Niggli M, Kempton C, et al. Haemophilia. 2022;28(6):1033–1043.
Hemophilia A and Mortality
Mortality in Congenital Hemophilia A - A Systematic Literature Review
Hay CRM, Nissen F, and Pipe SW. J Thromb Haemost. 2021;19(Suppl 1):6–20.
Establishment of a Framework for Assessing Mortality in Persons With Congenital Hemophilia A and Its Application to an Adverse Event Reporting Database
Pipe SW, Kruse-Jarres R, Mahlangu JN, et al. J Thromb Haemost. 2021;19(Suppl 1):21–31.
Application of a Hemophilia Mortality Framework to the Emicizumab Global Safety Database
Peyvandi F, Mahlangu JN, Pipe SW, et al. J Thromb Haemost. 2021;19(Suppl 1):32–41.
A Systematic Review of Mortality Statistics and Causes of Death in People With Congenital Hemophilia A (PwcHA)
Hay C, Nissen F, and Pipe S. Presented at NHF; August 1-8, 2020.
A Contemporary Framework for Understanding Mortality in People With Congenital Hemophilia A (PwcHA)
Pipe S, Kruse-Jarres R, Mahlangu J, et al. Presented at NHF; August 1-8, 2020.
An Analysis of Fatalities in Persons With Congenital Hemophilia A Reported in the FDA Adverse Event Reporting System (FAERS) Database
De Ford C, Kuebler P, Shang A, et al. Presented at NHF; August 1-8, 2020.
Impact of Inhibitors on Hemophilia A Mortality in the United States
Walsh CE, Soucie JM, Miller CH, et al. Am J Hematol. 2015;90:400–405.
Real-World Experience
Journal articles describing efficacy, safety, or surgical outcomes related to emicizumab in ≥50 patients in a real-world registry setting.
Bleeding Control Improves After Switching to Emicizumab: Real-World Experience of 177 Children in the PedNet Registry
van der Zwet K, de Kovel M, Motwani J, et al. Haemophilia. 2024;30(3):685–692.
Intraindividual Bleeding Outcomes in Patients With Hemophilia A on Emicizumab Prophylaxis in Australia
Ramanan R, Parikh S, Aung LL, et al. Blood Vessels Thromb Hemost. 2024;1(1):100005.
Emicizumab Prophylaxis in Haemophilia A With Inhibitors: Three Years Follow-Up From the UK Haemophilia Centre Doctors' Organisation (UKHCDO)
Wall C, Xiang H, Palmer B, et al. Haemophilia. 2023;29(3):743–752.